Evidence map›Paper›PMID 38212640›Full record

ArticleCommunications biology2024

Selection of extended CRISPR RNAs with enhanced targeting and specificity.

Ashley Herring-Nicholas, Hillary Dimig, Miranda R Roesing, Eric A Josephs

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. TOP-SECRETS enables Cas9 nucleases to discriminate SNVs outside of PAMs.bioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Ashley Herring-Nicholas *Department of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC, USA.
Hillary Dimig *Department of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC, USA.
Miranda R RoesingDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC, USA.
Eric A JosephsDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC, USA. eajoseph@uncg.edu.ORCID 0000-0002-5330-6842

Funding

Complex Mechanisms of Mutation and Mutation Avoidance in Living CellsR35GM133483 · NIGMS · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI JOSEPHS, ERIC ALAN · 2019 to 2023
$1.6M
A Molecular Grammar for Guide RNAs (gRNAs) with Engineered Secondary StructuresR21EB033595 · NIBIB · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI JOSEPHS, ERIC ALAN, MO, YIRONG · 2022 to 2023
$400k
NIBIB NIH HHS R21 EB033595NIGMS NIH HHS R35 GM133483
6 · The paper itself

Abstract

As CRISPR effectors like Cas9 increasingly enter clinical trials for therapeutic gene editing, a future for personalized medicine will require efficient methods to protect individuals from the potential of off-target mutations that may also occur at specific sequences in their genomes that are similar to the therapeutic target. A Cas9 enzyme's ability to recognize their targets (and off-targets) are determined by the sequence of their RNA-cofactors (their guide RNAs or gRNAs). Here, we present a method to screen hundreds of thousands of gRNA variants with short, randomized 5' nucleotide extensions near its DNA-targeting segment-a modification that can increase gene editing specificity by orders of magnitude-to identify extended gRNAs (x-gRNAs) that effectively block any activity at those off-target sites while still maintaining strong activity at their intended targets. X-gRNAs that have been selected for specific target / off-target pairs can significantly out-perform other methods that reduce Cas9 off-target activity overall, like using Cas9 variants engineered for higher specificity in general, and we demonstrate their effectiveness in clinically-relevant gRNAs. Our streamlined approach to efficiently identify highly specific and active x-gRNAs provides a way to move beyond a one-size-fits-all model of high-fidelity CRISPR for safer and more effective personalized gene therapies.

Indexed as

CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsGene EditingGenetic TherapyHumansRNARNARNA, Guide, CRISPR-Cas Systems

Identifiers

PMID38212640
PMCPMC10784525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.